Drug Trial Radar · NCT05046314
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Mar 12, 2024
Primary completion
Feb 5, 2025
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).
Conditions
- Sarcoma, Ewing
Interventions
TK216+VincristinBiological
TK216 was continuously administered for 14 days,then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle,every 28 days is a study cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (IRC)Time frame: Up to 2 years after TK216 introduction
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Tianjin Medical University Cancer Institude & Hospital
Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.